{"id":"liquid-palivizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Otitis media"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Palivizumab neutralizes RSV by targeting the F protein, which is essential for viral fusion with respiratory epithelial cells. By blocking this protein, the antibody prevents RSV from infecting cells and reduces viral replication. This passive immunization approach provides immediate protection against RSV infection.","oneSentence":"Palivizumab is a monoclonal antibody that binds to the fusion (F) protein on the surface of respiratory syncytial virus (RSV), preventing viral attachment and entry into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:39.431Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of respiratory syncytial virus (RSV) disease in high-risk infants and young children, including those with congenital heart disease, chronic lung disease, or immunodeficiency"}]},"trialDetails":[{"nctId":"NCT06851806","phase":"NA","title":"Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":138},{"nctId":"NCT04540627","phase":"PHASE1","title":"Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2020-07-06","conditions":"Healthy Adult Participants","enrollment":56},{"nctId":"NCT00233064","phase":"PHASE4","title":"Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2005-10","conditions":"Chronic Lung Disease","enrollment":417},{"nctId":"NCT02016690","phase":"","title":"Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Respiratory Syncytial Virus Infection","enrollment":312},{"nctId":"NCT00316264","phase":"PHASE2","title":"Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-04","conditions":"Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age","enrollment":260},{"nctId":"NCT00240929","phase":"PHASE2","title":"A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-09","conditions":"-Unhealthy Children With a History of Prematurity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Synagis"],"phase":"marketed","status":"active","brandName":"Liquid Palivizumab","genericName":"Liquid Palivizumab","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Palivizumab is a monoclonal antibody that binds to the fusion (F) protein on the surface of respiratory syncytial virus (RSV), preventing viral attachment and entry into host cells. Used for Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients, including premature infants and children with congenital heart disease or chronic lung disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}